Copeland Capital Management LLC Purchases 63,022 Shares of Perrigo Company plc (NYSE:PRGO)

Copeland Capital Management LLC increased its stake in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,452,786 shares of the company's stock after acquiring an additional 63,022 shares during the quarter. Perrigo makes up 1.4% of Copeland Capital Management LLC's investment portfolio, making the stock its 20th largest position. Copeland Capital Management LLC owned approximately 1.80% of Perrigo worth $68,776,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in Perrigo by 6,828.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,845,539 shares of the company's stock worth $201,710,000 after buying an additional 7,732,309 shares during the period. Norges Bank purchased a new stake in Perrigo in the 4th quarter worth approximately $36,614,000. Ion Asset Management Ltd. lifted its holdings in Perrigo by 50.1% in the 4th quarter. Ion Asset Management Ltd. now owns 2,820,000 shares of the company's stock worth $72,502,000 after buying an additional 941,667 shares during the period. BW Gestao de Investimentos Ltda. lifted its holdings in Perrigo by 111.6% in the 4th quarter. BW Gestao de Investimentos Ltda. now owns 1,097,192 shares of the company's stock worth $28,209,000 after buying an additional 578,597 shares during the period. Finally, Boone Capital Management LLC lifted its holdings in Perrigo by 126.1% in the 4th quarter. Boone Capital Management LLC now owns 1,022,369 shares of the company's stock worth $26,285,000 after buying an additional 570,148 shares during the period. 95.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Wall Street Zen cut Perrigo from a "buy" rating to a "hold" rating in a report on Friday. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Perrigo presently has an average rating of "Hold" and an average target price of $33.00.

Perrigo Stock Down 0.1%

NYSE:PRGO traded down $0.02 during trading hours on Friday, reaching $26.55. 952,191 shares of the company traded hands, compared to its average volume of 1,456,534. The business's 50-day moving average price is $26.31 and its two-hundred day moving average price is $26.01. The stock has a market capitalization of $3.65 billion, a P/E ratio of -20.27 and a beta of 0.46. Perrigo Company plc has a 1 year low of $23.14 and a 1 year high of $30.93. The company has a current ratio of 2.36, a quick ratio of 1.28 and a debt-to-equity ratio of 0.82.

Perrigo (NYSE:PRGO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.56 by $0.04. The business had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm's quarterly revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.29 earnings per share. Analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th were issued a $0.29 dividend. This represents a $1.16 dividend on an annualized basis and a dividend yield of 4.37%. The ex-dividend date of this dividend was Friday, May 30th. Perrigo's payout ratio is -88.55%.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.